arrow
A

Angela M. Krackhardt

technical university of munich
H指数:30
被引数:7,903

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Boosting CAR T-Cell Efficacy by Blocking Proteasomal Degradation of Membrane Antigens

通过阻断膜抗原的蛋白酶体降解来增强CAR T细胞疗效

Blood
IF23.1
2025-07-140
OAAI
High-resolution profile of neoantigen-specific TCR activation links moderate stimulation to increased resilience of engineered TCR-T cells
2024-12-030
OAAI
Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification (vol 14, 4632, 2023)

蛋白质基因组分析揭示RNA作为肿瘤无关的新抗原鉴定的来源 (第14卷,4632,2023)

2024-03-150
OAAI
Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification
2023-08-0216
OAAI
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
2023-07-3137
OAAI
Genomics-based personalized oncology of advanced thymic epithelial tumors
2023-04-040
PRE
Deep learning boosts sensitivity of mass spectrometry-based immunopeptidomics (vol 12, 3346, 2021)
2021-06-232
OAAI
Deep learning boosts sensitivity of mass spectrometry-based immunopeptidomics

深度学习提高了基于质谱的免疫流行病学的灵敏度

2021-06-0798
OAAI
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (vol 25, pg 1915, 2019)
2020-06-196
OAAI
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

转移性黑色素瘤患者PD1阻断的临床结果的整合分子和临床模型

2019-12-02606
OAAI
Key Features Relevant to Select Antigens and TCR From the MHC-Mismatched Repertoire to Treat Cancer

与从MHC不匹配的库中选择抗原和TCR相关的关键特征来治疗癌症

2019-06-287
OAAI